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IgLON family is composed of five genes: Lsamp, Ntm, Opcml, Negr1, and Iglon5;
encoding for five highly homologous neural adhesion proteins that regulate neurite
outgrowth and synapse formation. In the current study we performed in silico analysis
revealing that Ntm and Opcml display similar genomic structure as previously reported
for Lsamp, characterized by two alternative promotors 1a and 1b. Negr1 and Iglon5
transcripts have uniform 5′ region, suggesting single promoter. Iglon5, the recently
characterized family member, shares high level of conservation and structural qualities
characteristic to IgLON family such as N-terminal signal peptide, three Ig domains, and
GPI anchor binding site. By using custom 5′-isoform-specific TaqMan gene-expression
assay, we demonstrated heterogeneous expression of IgLON transcripts in different
areas of mouse brain and several-fold lower expression in selected tissues outside central
nervous system. As an example, the expression of IgLON transcripts in urogenital and
reproductive system is in line with repeated reports of urogenital tumors accompanied by
mutations in IgLON genes. Considering the high levels of intra-family homology shared by
IgLONs, we investigated potential compensatory effects at the level of IgLON isoforms
in the brains of mice deficient of one or two family members. We found that the lack
of IgLONs is not compensated by a systematic quantitative increase of the other family
members. On the contrary, the expression of Ntm 1a transcript and NEGR1 protein was
significantly reduced in the frontal cortex of Lsamp-deficient mice suggesting that the
expression patterns within IgLON family are balanced coherently. The actions of individual
IgLONs, however, can be antagonistic as demonstrated by differential expression of Syp
in deletion mutants of IgLONs. In conclusion, we show that the genomic twin-promoter
structure has impact on both anatomical distribution and intra-family interactions of
IgLON family members. Remarkable variety in the activity levels of 1a and 1b promoters
both in the brain and in other tissues, suggests complex functional regulation of IgLONs
by alternative signal peptides driven by 1a and 1b promoters.
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INTRODUCTION
IgLON family is composed of five neural adhesion proteins:
OPCML (OBCAM; IgLON1; Schofield et al., 1989), NTM
(IgLON2; Struyk et al., 1995), LSAMP (IgLON3; Horton and
Levitt, 1988), NEGR1 (KILON; IgLON4; Funatsu et al., 1999),
and IgLON5 (Grimwood et al., 2004; Sabater et al., 2014) (names
are based onHGNCnomenclature; http://www.genenames.org/).
IgLON family members are characterized by three Ig domains
and glycosylphosphatidylinositol (GPI) anchor (Sellar et al., 2003;
Pimenta and Levitt, 2004). IgLONs form homo- and heterophilic
dimers in cis within family and act in trans (between cells) on
the plane of the membrane as part of a larger signaling complex
(Reed et al., 2004; McNamee et al., 2011). All IgLON family
members are expressed both in neurons and oligodendrocytes
except for NTM, which has been found to express specifically
in neurons (Sharma et al., 2015). OPCML, NTM, LSAMP, and
NEGR1 regulate neurite outgrowth and participate in synapse
formation (Struyk et al., 1995; Mann et al., 1998; Gil et al.,
2002; Hashimoto et al., 2009; Sugimoto et al., 2010; Akeel et al.,
2011). Surprisingly, accumulating data confirms that IgLON
neural adhesion molecules can function as tumor-suppressor
genes in a number of non-neural organs and tissue types (Sellar
et al., 2003; Ntougkos et al., 2005; Reed et al., 2007; Cui et al.,
2008; Barøy et al., 2014; Kim et al., 2014). The early onset of
expression during embryogenesis and continuous requirement in
adulthood suggests that IgLONs have important roles throughout
the life cycle and are implicated in disease states (Schwarz et al.,
2009). For example, polymorphisms in Negr1 gene have been
associated with white matter integrity (Dennis et al., 2014),
depression (Hyde et al., 2016), and obesity (Melén et al., 2010;
Hotta et al., 2011; Elks et al., 2012; Poveda et al., 2014) in
several genome wide association studies. LSAMP is implicated
in the regulation of emotional and social behavior in mouse
models (Innos et al., 2011, 2012, 2013b; Philips et al., 2015)
and has been associated with psychiatric disorders such as major
depressive disorder and schizophrenia in humans (Behan et al.,
2009; Koido et al., 2012, 2014; Innos et al., 2013a). A number of
publications emphasize the role of OPCML as tumor-suppressor
in different tumor types (Cui et al., 2008; McKie et al., 2012).
Polymorphisms in NTM gene, the closest kindred to OPCML,
have been associated with intelligence (Pan et al., 2011) and
shown to participate in axon fasciculation (Chen et al., 2001;
Yu et al., 2012). Iglon5, a newly discovered member of the
IgLON family, has a role in encephalopathy with prominent
sleep dysfunction, chronic neurodegeneration, and cell-surface
autoimmunity (Sabater et al., 2014; Leypoldt et al., 2015).
We have previously demonstrated differential promoter
activity of two alternative promoters in Lsamp gene (Philips
et al., 2015). The expression pattern of two promoters diverges
from the developmental initiation to adulthood and is likely
related to the fine tuning of neural pathways during development.
The expression of 1a isoform of Lsamp gene is dominant in
“classic” limbic structures, particularly in the hippocampus and
amygdaloid area. 1b isoform is prevalent in the sensory nuclei
of thalamus and cortical sensory areas (Philips et al., 2015).
These findings underline the importance of studying 1a and
1b promoter activities independently in the IgLON family. The
sequences of 1a and 1b transcripts of Lsamp gene in human,
mouse, and rat were initially described by Pimenta and Levitt
(2004). However, no valid analysis of the structure and possible
alternative promoters exists for other genes of the IgLON family.
Bioinformatic analysis of first exon structure of IgLON genes
for mouse, rat, and human was carried out to ascertain the
sequences and the number of active promoters for each gene. We
thereafter designed a customized 5′-isoform-specific quantitative
real-time PCR (qPCR) assay to distinguish between alternative
promoter products ofOpcml,Ntm, and Lsamp in mice. Our study
provides the first comprehensive characterization of the IgLON
family transcription pattern in the mouse brain. Considering
that the tumor-suppressor role of IgLON proteins has repeatedly
been affirmed in a variety of organs, we also evaluated the
expression of IgLON transcripts in 12 non-neural tissues.
Although IgLONs have been reported to have essential function
in development of neural cirquits, no gross anatomy changes
have been reported in the brains of mice deficient for IgLON
proteins (Lee et al., 2012; Philips et al., 2015; Mazitov et al.,
2017). Considering the high levels of intra-family homology
shared by IgLON adhesion molecules, potential compensatory
effects within IgLON gene family were also studied: we estimated
promoter activities in the frontal cortex and hippocampi of mice
with deletion mutation in Lsamp (Lsamp−/−), Ntm (Ntm−/−),
or in both (Lsamp−/−/Ntm−/−) genes. Finally, the expression of
Synaptophysin, a marker of synaptogenesis, was studied in the
same mutant mice to gain insight to the intra-family interactions
in functional systems.
MATERIALS AND METHODS
In silico Analysis of Alternative First Exons
and Protein Domains
Bioinformatic analysis of alternative first exons and respective
upstream regions (5′UTR) of rodent and human Opcml and
Ntm transcripts was performed by detecting potential analogy
with the known structure of Lsamp gene (Pimenta and Levitt,
2004). For a better reference, we discriminate between two
parts in exon 1b (Figure 1A): 1b’ (first part, specifically added
to 1b transcripts) and 1b” (second part of exon 1b, which is
included into all isoforms of Opcml, Ntm, Lsamp transcripts).
Analogous gene structure was confirmed by respective alignment
of Opcml, Ntm, and Lsamp 1a and 1b transcripts with Clustal
Omega Multiple sequence alignment service (http://www.ebi.
ac.uk/Tools/msa/clustalo/). Alternative transcripts were further
confirmed by mapping representative EST sequences to both
transcripts. A more detailed analysis of rodent and human
transcripts was carried out by blasting potential I exon and II
exon or their combination sequences against EST database. High
quality ESTs spanning upstream of I or II exon were subsequently
aligned to confirm the existence or lack of alternative first
exons. Potential transcripts were confirmed by BLAST search
in NCBI Refseq and Non-Refseq databases (Altschul et al.,
1990). MEGA5 software was used to align EST sequences to
transcripts (Tamura et al., 2011). Opcml and Ntm 1a promoter
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FIGURE 1 | Twin promoter structure of Opcml, Ntm, and Lsamp genes and alignment of alternative 5′ fragments of the coding region. (A) Genomic
structure and assembly of the 5′ part of 1a and 1b promoter derived transcripts. The core of the schema has been adapted from Pimenta and Levitt (2004). The 5′
part of 1b transcript is assembled by adding up 1b’ + 1b” + exon 2, followed by the downstream exons in both rodent and human. The 5′ part of 1a transcript is
typically assembled by adding up 1a + 1b” + exon 2, followed by the downstream exons. Exception of this is Lsamp 1a transcript in rodents where one extra exon
(1a’) is included: 1a +1a’ +1b” + exon 2. Horizontal arrows denoted as 1aF and 1bF indicate transcript specific forward primers on 1a and 1b first exon respectively.
Horizontal arrow denoted as uniR indicates universal reverse primer on exon 2 and # denoted as uniP indicates custom probe on 1b”. *Ntm and Opcml are located in
the same chromosome locus. (B) Alignment of unique 1a and 1b transcript specific 5′ sequences of Ntm and Opcml in rodent and human with corresponding Refseq
or Non-Refseq accession numbers. NA refers to “accession number not available,” indicating rat 1a sequences that were missing from the NCBI/Ensembl.org
database at the time of the analysis and were therefore amplified and analyzed for the current study. More information about accession numbers can be found in
Supplementary Tables S1–S3.
specific transcripts for rat were not available in NCBI nor
Ensembl databases (accessed at 20/06/16) and were therefore
amplified from the cDNA pool derived from the brains of
male Sprague-Dawley rats and confirmed by sequencing. The
alignment of Opcml and Ntm 1a promoter specific transcripts
for rat, along with respective sequences from human and
mice have been shown in Figure 1B. Other sequences used in
the current study were obtained from respective databases in
Ensembl (release 85) or NCBI. The genomic structure of Opcml
and Ntm was confirmed by sequencing alternative 5′-regions of
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the transcripts presented in Figure 1B. The sequence identity
numbers obtained from Ensembl database and accession codes
available in NCBI RefSeq/Non-RefSec databases referring 1a and
1b isoform specific sequences have been shown in Supplementary
Tables S1, S2.
Conservation analysis was carried out to emphasize Iglon5
(Refseq NP_001157990/Uniprot Q8HW98) affiliation with the
IgLON family. The protein sequences for all IgLON isoforms
cited in Supplementary Table S3 were aligned in Supplementary
Figure S4. To highlight the 5′ region structure of IgLON proteins,
the amino-acid alignment of variable (1a/1b’) and universal (1b”
± II exon) parts of the proteins was performed (Figure 2).
The amino-acid sequence identity between functional regions
in IgLON family have been shown in Supplementary Tables
S5–S9. The N-terminal signal peptide region, immunoglobulin
domain sequences, and conserved cysteine residue locations
were acquired from Uniprot. PredGPI web service was
used to predict the location of GPI anchor binding sites
(Pierleoni et al., 2008). All the alignments of either DNA and
amino-acid sequences were performed by using the Clustal
FIGURE 2 | Alignment of first and second exon specific amino acid sequences encoded by 8 known IgLON transcripts in mouse. 1a or first part of exon
1b (1b’) is separated by vertical dashed line from universally added exon 1b”. Underlined sequence indicates extra exon 1a’ of Lsamp 1a transcript. First exons 1a
(1a’) or 1b’ code for signal peptides. 1b” is separated by second dashed line from universally added exon 2. Exons 1b” and 2 code for first immunoglobulin domain
indicated by box. # Indicates two conserved cysteine residues in the first Ig domain.
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Omega Multiple sequence alignment program (Sievers et al.,
2011).
Animals
Detailed description of the creation of Lsamp-deficient mice
with a LacZ transgene has been described by Innos et al.
(2011). Ntm gene heterozygous mutant strain (032496-UCD
B6;129S5-Ntmtm1Lex/Mmucd) were procured from the Mutant
Mouse Regional Resource Center at UC Davis (https://www.
mmrrc.org/catalog/sds.php?mmrrc_id=32496) as described in
Mazitov et al. (2017). The strategy for creation of Ntm-deficient
mice was analogous to that of Lsamp-deficient mice as the
exon 1b has been deleted, leading to the disruption of all
functional Ntm transcripts. For obtaining Lsamp−/−, Ntm−/−,
Lsamp−/−/Ntm−/−, and Wt mice for compensatory studies, we
used the following scheme: first we created Lsamp+/−/Ntm+/−
animals by crossing Lsamp−/− and Ntm−/− mice; followed
by crossing double heterozygous mice providing the necessary
genotypes. C57BL/6 Bkl mice (ScanburAB, Sollentuna, Sweden)
were used for collecting tissue samples from brain and other
organs to describe the expression of IgLONs in wild-type mouse.
The cDNA pool from the brain of Male Sprague-Dawley rats
was used for sequencing Opcml and Ntm 1a 5′ regions for
rat (Figure 1A). Breeding and housing was performed in the
Institute of Biomedicine and Translational Medicine, University
of Tartu. Mice were housed in 1264C Eurostandard type II cages
(Tecniplast) measuring 268 × 215 × 141 mm. Cages contained
aspen chips for bedding and aspen wool for nesting material
which was replaced once a week. Each cage contained 7–8
animals based on allocation after weaning. The animals were
maintained under 12-h light/dark cycle, with lights on at 7:00
a.m. and they had ad libitum access to food and water. All animal
procedures in this study were performed in accordance with the
European Communities Directive (86/609/EEC) and permit (No.
29, April 28, 2014) from the Estonian National Board of Animal
Experiments.
Tissue Collection
The dissection of mouse brain was performed according to
coordinates obtained from the mouse brain atlas (Franklin and
Paxinos, 1997). Full mouse brain was divided into 17 areas to
enable optimal brain-wide coverage. The areas dissected from
the brain were as follows: areas of the cerebral cortex (frontal,
parietal, occipital, and temporal cortex, the latter also including
amygdaloid complex), the basal forebrain structures (caudate
putamen, ventral striatum, septum pellucidum, hippocampus),
the structures of the diencephalon (thalamus, hypothalamus, and
pituitary gland), midbrain (including colliculi), pons, cerebellum,
medulla oblongata, and spinal cord. Eyes with optic tract were
also included in the list of neural tissues. We also dissected non-
neural tissues including skeletal muscle, heart, lung, liver, small
intestine, adrenal glands, kidney, male ureter, ductus deferens,
testis, ovary, and uterus. At least three biological replicates (n ≥
3) from each tissue were separated for the estimation. The tissue
samples were individually dissected, immediately frozen in liquid
nitrogen after dissection and stored in the −80◦C freezer until
further analysis (qPCR or western blot).
Two-Step qRT-PCR (qPCR)
IgLON transcript levels were determined by two-step RT-qPCR
(qPCR). Total RNA was extracted from each tissue sample
by the use of Trizol reagent (Invitrogen) according to the
manufacturer’s protocol. First strand cDNA was synthesized
by the use of Random Hexamer (Applied Biosystems) and
SuperScriptTM III Reverse Transcriptase (Invitrogen) according
to the manufacturer’s protocol. Quantitative TaqMan Assay with
FAM-BHQ-probe was designed for the detection ofOpcml 1a/1b,
Ntm 1a/1b, Negr1, and Iglon5 transcripts. Lsamp 1a/1b were
detected as described previously in Philips et al. (2015). In
case of Opcml, Ntm, and Lsamp universal reverse primer was
combined with an alternative forward oligo specific for either
1a or 1b transcript. The approximate positions of primers used
for amplification have been shown as bold arrows in Figure 1A.
Custom TaqMan Probe was designed to bind to the universal
1b′′ exon. Synaptophysin mRNA levels were determined by
using the predesigned Taqman Gene Expression Assays (Applied
Biosystems): Mm00436850_m1 (previously used also in Heinla
et al., 2015). TaqMan Universal PCR Master Mix was used
according to the manufacturer’s protocol as reaction buffer. Two
microgram of RNA was used in 20 µl end reaction for cDNA
synthesis from brain tissues. Three microgram of RNA was
used in 20 µl end reaction for cDNA synthesis from organ
tissues. cDNA was diluted three times before 2.15 µl of cDNA
was added per 42.3 µl reaction mix. Each reaction mix was
divided out in 10µl quadruplicates. ABI Prism 7900HT Sequence
Detection System with ABI Prism 7900 SDS 2.4.2 software
(Applied Biosystems) was used for qPCR detection.
Protein Extraction and Western Blotting
Eppendorf tubes containing the dissected mouse frontal cortex
were snap-frozen in liquid nitrogen and stored at −80◦C until
use. Frozen tissues were sonicated in ice cold RIPA buffer
(ThermoFisher Scientific) supplemented with protease inhibitor
(Life Technologies). Protein lysates were centrifuged for 10
min 12,000 g at 4◦C. Supernatant was collected and protein
concentration was determined by BCA method (Pierce BCA
Protein Assay Kit, Thermo Scientific). Samples were frozen
at −80◦C for long-term storage. NuPAGE Electrophoresis
System (Life Technologies) components and equipment were
used according to the manufacturer’s instructions. For western
blotting, membranes were blocked in 3% dry milk on a rocker
for 60 min at RT. Next, membranes were incubated with mouse
anti-Negr1 (1:200) (sc-393293, Santa Cruz), mouse anti-Ntm
(1:200) (sc-390941, Santa Cruz), or rabbit anti-GAPDH (1:10K)
(247002, Synaptic Systems) primary antibodies 60 min at RT
and thereafter o/n at 4◦C under gentle agitation. All primary
antibodies were diluted in 3% dry milk with 0.1% Tween-20.
After primary antibody incubation the membranes were washed
six times in Milli-Q water and incubated with corresponding
secondary antibodies for 1 h at RT under agitation. Secondary
antibodies goat anti-mouse antibody (A21057, Invitrogen) and
goat anti-rabbit antibody (35569, Jackson ImmunoResearch)
were diluted in PBS-0.1% Tween-20 1:15K and 1:40 K,
respectively. After incubation with secondary antibodies the
membranes were washed six times in Milli-Q water followed by
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20-min wash with PBS-0.1% Tween-20 with shaking. Re-Blot
Plus Strong Solution (1x) (2504, Millipore) was used to strip and
re-use membrane. Antibody detection was performed using the
LI-COR Odyssey CLx system (LI-COR Biotechnologies). Images
were converted to grayscale and quantification was performed
using Image Studio Lite v 3.1.4 (LI-COR Biotechnologies).
Relative protein expression levels for NEGR1 and NTM were
obtained after normalization to GAPDH.
Data Analysis and Presentation
All qPCR data has been presented in the linear scale, in form of
2−1CT (Livak and Schmittgen, 2001) where1CT is the difference
in cycle threshold (CT) between the gene of interest (FAM) and
housekeeper gene Hprt1 (VIC). The use of internal control gene,
Hprt1, has been carefully optimized in our previous studies (Raud
et al., 2009) and has been proved to be one of the most stable
housekeeping gene across different organs and tissue types also
in other studies (Svingen et al., 2015). The exact 2−1CT values
(± SEM) in the brain and non-neural tissues have been presented
in Supplementary Tables S10, S11; illustrative histograms depict
expression data for selected tissues in Supplementary Figure
S12. The brain-wide relative distribution of the expression levels
of IgLON transcripts have been visualized in Figure 3. The
numerical difference between minimum and maximum values
of 2−1CT was defined as expression range for each gene. The
expression range was then divided into 10 ranks and converted
to 10 grayscale shades from white to black, representing minimal
(1–10%) to maximal (90–100%) intensity accordingly. The
relative expression levels for each IgLON transcript in the
mouse non-neural tissues has been presented in Table 1. The
exact numerical values (mean 2−1CT SEM) are available in the
Supplementary Table S11. For a better overview, the expression
levels detected by qPCR were categorized as firm (+ + +; the
mean 2−1CT ≥0.1), modest (++; the mean 2−1CT ≥0.01), and
minimal (+; the mean 2−1CT ≥0.001). The estimations were
given if the transcript specific amplicon was detected in at least
three biological replicates and further corrected according to the
quality of the amplification curve (Sisti et al., 2010).
Statistical Analysis of Gene and Protein
Expression Data in Mutant Mice
Alterations of IgLON gene expression levels in the frontal cortex
and hippocampus of wild-type and mutant mice (Figures 4, 6)
were analyzed by one-way ANOVA in parallel in two mutant
subgroups (Supplementary table S13): Group I included Wt
(wild-type), Lsamp−/−, Lsamp−/−/Ntm−/−, and Group II
included Wt, Ntm−/−, Lsamp−/−/Ntm−/− at significance level
of α = 0.05. Intra-group differences were further emphasized
in separate mutant groups by Tukey’s HSD-test carried out on
significance level of α= 0.05. Twomutant groups, Lsamp−/− and
Ntm−/−, were further compared by Student’s t-test at significance
level of α = 0.05. In Western blot data analysis of relative
protein expression levels for NTM and NEGR1 were normalized
to GAPDH (Supplementary Figures S16, S17) and Student’s t-
test was used to detected statistically significant differences at
significance level of α = 0.05 (Figure 5). Wild-type correlation
analysis of IgLON expression levels in the frontal cortex
and hippocampus was carried out with parametric Pearson
correlation test at significance level of α = 0.05 to emphasize
coherent expression within the family (Supplementary Figures
S18, S19). The Shapiro-Wilks W-test preceded all gene and
protein expression analysis to test for the normality assumption
of the data using significance level of α= 0.05.
RESULTS
In silico Analysis of Iglon Transcripts and
Proteins
In silico analysis of alternative first exons confirmed the existence
of twin promoter structure for Opcml, Ntm, and Lsamp genes
in rodent and human. The schematic representation of twin
promoter structure of Opcml, Ntm, and Lsamp genes has been
shown in Figure 1A. The alignments of unique promoter specific
5′ sequence fragments of transcripts can be viewed in Figure 1B
and alignment of amino-acid sequences of 5′ region in IgLONs
have been presented in Figure 2. Different isoforms and potential
variants of exon structure of IgLON family transcripts based on
Ensembl.org database can be viewed in Supplementary Tables
S1, S2. Available EST sequences and blast searches also support
the existence of both promoter specific transcripts for all three
genes. Negr1 and Iglon5 in mouse have a uniform 5′ end
of the transcript, suggesting single promoter. The number of
alternative variants in the 3′ region of IgLON transcripts is
remarkable, for example, the mouse Negr1 gene is confirmed to
have two alternative transcripts based on EST alignments, both
of which have alternative 3′ ends (NM_001039094/NM_177274;
Supplementary Table S3). However, the variation in the 3′ end
region was not in the focus of the current study and will be
addressed separately in the future. Iglon5, the most recently
discovered family member, has currently support for only one
transcript for rodent and human based on EST data, indicating
single promotor. IGLON5 spans 336 amino acids and is on the
protein level closest to OPCML (50%), NTM (48–49%), and
LSAMP (46–47%), and least similar to NEGR1 (41%). IgLON5, as
all IgLONs, has N-terminal signal peptide, three pairs of cysteine
residues and three C2 immunoglobulin domains (Supplementary
Figure S4). Cysteine residues are highly conserved as expected as
they form disulfide bridges to stabilize immunoglobulin domain
structure. GPI prediction service indicated all IgLON transcripts
to have putative GPI binding site. OPCML 1a/1b, NTM 1a/1b,
and IGLON5 have conserved residue position (N) for GPI
binding. Alternative 3′ end isoforms of LSAMP (1a/1b) and
NEGR1 (A0A4W9/Q80Z24) have alternative GPI binding sites
(Supplementary Figure S4). Average overall similarity of IgLONs
varies from as high as 72% between OPCML and NTM to
as low as 41% between NEGR1 and IGLON5 (Supplementary
Table S5). Overall conservation is the highest in immunoglobulin
domains (Supplementary Tables S7–S9) and the lowest in the area
coding for signal peptide (Supplementary Table S6). Comparison
of domains reveals the first two immunoglobulin domains to
be more conserved. Conservation varies from as high as 91%
between OPCML and NTM to as low as 42% between NEGR1
and IGLON5 in domain I, 71% between OPCML and NTM to as
Frontiers in Neuroscience | www.frontiersin.org 6 February 2017 | Volume 11 | Article 38
Vanaveski et al. Promoter-Specific Expression of IgLONs
FIGURE 3 | The brain-wide expression distribution of eight IgLON transcripts based on relative expression intensity measured by qPCR. (A) Lsamp 1a,
(B) Lsamp 1b, (C) Ntm 1a, (D) Ntm 1b, (E) Opcml 1a, (F) Opcml 1b, (G) Negr1, and (H) IgLon5. The numbers on the mouse brain image (1–18) represent regions:
eye (1), olfactory bulb (2), frontal cortex (3), parietal cortex (4), occipital cortex (5), temporal cortex including amygdaloid complex (9), caudate putamen (6), ventral
striatum (7), septum pellucidum (8), hippocampus (10), thalamus (11), hypothalamus (12), pituitary gland (13), midbrain including colliculi (14), cerebellum (15), pons
(16), medulla oblongata (17), and spinal cord (18). The 10-level gray-scale shades from white to black represent minimum (1–10%) to maximum (90–100%) expression
levels respectively. The range of 10 intervals was achieved by dividing the difference of 2−1CT minimum to maximum values separately for each gene. The exact
2−1CT values (±SEM) for all qPCR data in the brain and non-neural tissues have been presented in Supplementary Table S10.
low as 47% between NEGR1 and IGLON5 in domain II and 74%
between OPCML and NTM to as low as 45% between NEGR1
and IGLON5 in domain III.
The Expression of IgLON Transcripts in the
Mouse Brain
The brain-wide distribution of all IgLON genes is
highly heterogeneous across the anatomical regions and
across individual transcripts. The grayscale illustrations
(Figures 3A–H) represent relative expression pattern within
each gene including its alternative transcripts: all IgLON genes
with alternative promoters 1a and 1b (Figures 3A–F) reveal
remarkable dissimilarity in the activity levels of two promoters
in different brain areas just as we have previously demonstrated
for Lsamp in Philips et al. (2015). Lsamp 1a (Figure 3A) is more
intensively expressed in the hippocampal area than Lsamp 1b
(Figure 3B), on the contrary, the expression of Lsamp 1b is more
intense in the cerebellum, compared with Lsamp 1a transcript.
Likewise, the general expression patterns of Lsamp transcripts
are in line with our previous studies (Heinla et al., 2015; Philips
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TABLE 1 | The expression of IgLON transcripts in mouse non-neural
tissues.
Lsamp Ntm Opcml Negr1 Iglon5
1A 1B 1A 1B 1A 1B
Skeletal muscle ++ +++ +++ +++
Heart +++ + ++ + ++ ++
Lung + ++ +
Liver + + + + ++
Small intestine + + + + +
Adrenal glands ++ ++ + + + + +++ +
Kidney + + ++ + + + ++ ++
Male ureter + + + + + +
Ductus deferens ++ + + + + ++ +
Testis + + + + + + ++ +++
Ovary + ++ ++ + ++ ++ ++
Uterus + + + + + + ++ +
The expression levels detected by quantitative real-time PCR were evaluated as firm
(+ + +), modest (++), and minimal (+). The conversion criteria have been given in the
“Methods” Section.
et al., 2015). As a novel finding, Lsamp 1a promoter has strong
activity in the eye (Figure 3A).
The expression activity of Ntm 1a and 1b promoters is
remarkably different. Ntm 1a promoter activity is the highest
in the frontal cortex and thalamus (Figure 3C), whereas 1b is
the most active in the cerebellum (Figure 3D). Likewise, the
expressional activity of Opcml 1a and 1b promoters is highly
dissimilar. The highest expression of Opcml 1a was detected in
the frontal cortex (Figure 3E), whereas the highest expression
of Opcml 1b was measured in the cerebellum (Figure 3F)
where 1a promoter has no detectable activity. However, both
promoters in Opcml are highly active in the olfactory bulb. Negr1
has the most intense expression levels in the temporal cortex
including amygdaloid complex and relatively high expression in
the cerebellum, cerebral cortex, and basal forebrain. The signal of
Negr1 transcript was minimal in the brainstem (midbrain, pons,
medulla, spinal cord) and in the eye (Figure 3G). The level of
Iglon5 transcript, on the contrary, was highest in the brainstem
(namely pons and medulla), thalamus and eye and weakest
in the hippocampus, septum, and pituitary gland (Figure 3H;
Supplementary Table S10).
The Expression of IgLON Transcripts
Outside the Central Nervous System in
Mouse
With a few exceptions, IgLON transcripts could be detected in
all non-neural tissues that we studied: in the skeletal muscles,
heart, lung, liver, small intestine, adrenal glands, kidney, male
ureter, ductus deferens, testis, ovary, and uterus (see Table 1
for overview and Supplementary Table S11 for exact expression
values represented in the units of 2−1CT).
Lsamp 1a and 1b transcripts have detectable expression across
the urogenital system. Promoter specific expression (only 1b
promoter is expressed) can be seen in the heart, skeletal muscle,
FIGURE 4 | The average mRNA expression level of IgLON transcripts in
Wt, Lsamp−/−, Ntm−/− , and Lsamp−/−/Ntm−/− mutant mice
measured by qPCR. Expression levels are presented for (A) frontal cortex
(FRO) and (B) hippocampus (HIP) based on promoter activity at the age of 4–5
months as 2−1CT ± SEM. For Opcml 1a/1b, Ntm 1a/1b, Lsamp 1a/1b and
Negr1 the left Y-axis applies and for Iglon5 (separated in the Figure by a
vertical dashed line from the other transcripts) the right Y-axis applies. n = 6 in
all groups; *p < 0.05; **p < 0.01; ***p < 0.001. One-way ANOVA was used for
every isoform in parallel in two mutant subgroups: Group I: Wt (wild-type),
Lsamp−/−, Lsamp−/−/Ntm−/−, and Group II: Wt, Ntm−/−,
Lsamp−/−/Ntm−/−. Intra-group differences were further emphasized by
Tukey’s HSD test. Two mutant groups Lsamp−/−and Ntm−/− were further
compared by Student’s t-test at significance level of α = 0.05. In the frontal
cortex, the expression level of Ntm 1a was lower in Lsamp−/− animals
compared to Wt. The expression level of Opcml 1a and Negr1 was lower in
Lsamp−/− animals compared to Ntm−/−. However, in the hippocampus, the
level of Iglon5 was significantly higher in Lsamp−/− animals compared to both
Wt and Lsamp−/−/Ntm−/− groups. More detailed information about
statistical findings can be found in the Sections Gene Expression Alterations in
Frontal Cortex and Gene Expression Alterations in Hippocampus.
and small intestine, which all consist specific types of muscle
cells. The activity of both Lsamp promoters was detectable in the
liver but there was no signal in the lungs. The expression of Ntm
is seemingly more selective. The signal for both promoters was
missing in the lungs, small intestine, male ureter, and skeletal
muscle. Both 1a and 1b promoters of Ntm gene are active in
the heart, kidneys, adrenal glands, testis, ovary, and uterus.
1b transcript specific signal was specifically detectable in the
liver and ductus deferens. Opcml mRNA specific signals were
detectable in all organs/tissue types studied; Opcml 1a promoter
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FIGURE 5 | The individual protein expression levels of NTM and NEGR1 in the frontal cortex of wild-type and Lsamp−/− mice measured by western
blot. (A) NTM and (B) NEGR1 expression levels are presented relative to GAPDH; n = 7; *p < 0.05. It is important to note that NTM antibody is not able to
discriminate between 1a and 1b isoforms, therefore the significant decrease of Ntm 1a in Lsamp−/− animals (Figure 4A) is only detectable in mRNA level.
was specifically active in the skeletal muscle, lungs, liver, and
ovaries; only Opcml 1b promoter was active in the heart. The
expression activity of Negr1 was detectable in all organs/tissue
types studied. Iglon5 mRNA was detectable in all other tissues
except liver.
Relative quantification was also used for the analysis of
non-neural tissues as our purpose was to gain insight to the
relative expression of IgLON transcripts in non-neural tissues
compared with the expression levels in the neural tissues.
All IgLONs have remarkably higher expression levels in the
neural tissues compared to any other non-neural tissue type.
However, the average fold-difference (average expression in
the brain/average expression in non-neural tissues; across all
samples) between expression in the brain and organs was
different in IgLON transcripts. The most homogenous body-
wide anatomical distribution was characteristic for Iglon5, as
the average expression in the brain was roughly only 4.5-fold
higher than the average Iglon5mRNA expression level in the non-
neural tissues. The expression difference (neural vs. non-neural)
was also lower for Negr1 (14.4-fold) and Lsamp 1b (16.6-fold)
transcripts. The other IgLON transcripts had considerably high
difference between the expression in the brain and the expression
in non-neural tissues (58.8-fold for Lsamp 1a, 51.7-fold for Ntm
1a, 55.5-fold for Ntm 1b; 61.3-fold for Opcml 1a, 93.7-fold for
Opcml 1b).
Gene Expression Alterations in the Brain of
Wild-Type and Mutant Mice
Gene Expression Alterations in Frontal Cortex
The expression values (mean 2−1CT ± SEM) for the IgLON
transcripts in the frontal cortex are presented in Supplementary
Table S14 and Figure 4A Expression alterations were detected for
Opcml 1a,Ntm 1a, andNegr1. A statistically significant difference
was observed in Group I [F(2, 15) = 3.81, one-way ANOVA p
= 0.046]. Further intra-group analysis did not reach statistical
significance between Wt and Lsamp−/− (Tukey HSD p = 0.06),
nor between Lsamp−/− and Lsamp−/−/Ntm−/− (Tukey HSD p
= 0.092). A statistically significant difference was detected for
Opcml 1a in comparison of different mutant lines Lsamp−/− and
Ntm−/− [F(2, 10) = 2.85, t-test p= 0.049]. The average expression
level of Ntm 1a transcript in the frontal cortex was significantly
reduced in Lsamp−/− compared to Wt [F(2, 10) = 2.66, t-test p
= 0.003]. The average expression level of Negr1 transcript in the
frontal cortex was reduced in Lsamp−/− compared to Ntm−/−
[F(2, 10) = 1.41, T-test p = 0.001; Figure 4A]. There were no
statistically significant effects in the expression of Syp in the
comparison of the frontal cortex of Wt and different mutant lines
(Figure 6).
Gene Expression Alterations in Hippocampus
The expression values (mean 2−1CT ± SEM) for the IgLON
transcripts in the hippocampus are presented in Supplementary
table S15 and Figure 4B. Expression changes were detected
for Iglon5 and Syp. For Iglon5 transcript in the hippocampus
a statistically significant difference was observed in Group I
[F(2, 15) = 6.8, one-way ANOVA p = 0.008]. Further intra-group
analysis revealed a significantly higher expression level in the
Lsamp−/− group as compared to Wt (Tukey HSD p = 0.045)
and Lsamp−/−/Ntm−/− (Tukey HSD p= 0.008; Figure 4B). The
expression levels of Syp in the hippocampus were significantly
different in Group II [F(2, 15) = 13.99, one-way ANOVA p =
0.0004]. Further intra-group analysis showed that the expression
was significantly higher in the Ntm−/− group as compared to Wt
(Tukey HSD p = 0.0004), Lsamp−/−/Ntm−/− (Tukey HSD p =
0.022), and Lsamp−/− [F(2,10) = 3.59, t-test p= 0.031; Figure 6].
Protein Expression in the Frontal Cortex
Selected effects on mRNA level were thereafter explored at
the protein level in the frontal cortex. NTM average protein
expression measured by western blot was lower in Lsamp−/−
(1; n = 7) mice when compared with the Wt (1.21; n = 7)
mice, however, this effect did not reach statistical significance
[F(2, 12) = 5.13, t-test p = 0.11; Figure 5A]. It is important to
note that NTM antibody is not able to discriminate between 1a
and 1b isoforms, therefore the significant decrease of Ntm 1a
in Lsamp−/− animals is only detectable in mRNA level. NEGR1
average protein expression was significantly lower in Lsamp−/−
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FIGURE 6 | The average mRNA expression level of Syp transcript in Wt,
Lsamp−/−, Ntm−/−, and Lsamp−/−/Ntm−/− mutant mice measured
by qPCR. Expression levels are presented for frontal cortex (FRO) and
hippocampus (HIP) based on promoter activity as 2−1CT ± SEM. n = 6 in all
groups; *p < 0.05; ***p < 0.001. One-way ANOVA was used for every isoform
in parallel in two mutant subgroups: Group I: Wt (wild-type), Lsamp−/−,
Lsamp−/−/Ntm−/−, and Group II: Wt, Ntm−/−, Lsamp−/−/Ntm−/−.
Intra-group differences were further emphasized by Tukey’s HSD test. Two
mutant groups Lsamp−/−and Ntm−/− were further compared by Student’s
t-test at significance level of α = 0.05. Statistically significant differences in Syp
expression were observed only in the hippocampus where the level was higher
in Ntm−/− animals than in Wt, Lsamp−/−/Ntm−/−, and Lsamp−/− animals.
More detailed information about statistical findings about Syp expression can
be found in the Section Gene Expression Alterations in Hippocampus.
(0.74; n = 7) mice when compared with Wt (0.96; n = 7) mice
[F(2, 12) = 2.74, t-test p= 0.023; Figure 5B].
DISCUSSION
Structural Characteristics of IgLONs
In the present study, we have performed a comprehensive
promoter-specific analysis of the anatomical distribution of
IgLON transcripts based on a thorough analysis of the genomic
and expressed sequences of the whole IgLON family. According
to our analysisNtm andOpcml display similar genomic structures
as Lsamp (Pimenta and Levitt, 2004) characterized by two
alternative promotors 1a and 1b, whereas Negr1 and Iglon5 have
a uniform 5′ end of the transcript, suggesting single promoter.
The alternative 5′ region 1a/1b is encoding for alternative N-
terminal signal peptides (Figure 2) which are most likely used to
target nascent proteins to specific cellular region. Signal peptides
are cleaved during post-translational modifications and the
processed polypeptides contain identical N-termini, indicating
that the complex alternative splicing process serves regulatory
mechanisms without altering the functional properties of the
protein (Pimenta and Levitt, 2004). Alternative promoters are
considerable mechanisms by which genes obtain functional
flexibility and diversity. For example, Bdnf gene in rodent and
human has nine promoters, which enable tissue-specific and
developmentally regulated expression of different isoforms. As in
case of IgLONs, these Bdnf isoforms have been reported to code
the same core part of protein, with alterations in signal peptide
(Pruunsild et al., 2007). Having multiple cell or tissue specific
promoters can provide opportunity for quick adaptation to a
changed environment (Xin et al., 2008). Furthermore, according
to our previous data, one of the IgLON protein, LSAMP, is
indeed implicated in the plasticity and adaptability in changing
environments (Innos et al., 2012; Heinla et al., 2015).
Based on our analysis, Iglon5, the recently characterized
family member, shares high level of conservation with all other
IgLON family members. Protein sequence level conservation
ranks IGLON5 to be closest to OPCML, NTM, LSAMP, and
least similar to NEGR1 (Supplementary Table S5). IGLON5
also shares structural qualities characteristic to IgLON protein
family: N-terminal signal peptide, GPI anchor binding site
and three pairs of cysteine residues for three immunoglobulin
domains (Figure 2; Supplementary Figure S4). The first two
immunoglobulin domains share the highest intra-family
conservation. Extending distally from the cell membrane, it
is likely that these domains are used for the formation of cis
and trans interactions within IgLON family, analogously with
the thoroughly described intra-family dimerization pattern of
Nectins (Narita et al., 2011).
Expression of IgLON Transcripts Outside
the Central Nervous System in Mouse
It has been emphasized for decades that IgLON adhesion
molecules are specific for the central nervous system (CNS)
(Horton and Levitt, 1988; Pimenta et al., 1995). Most of the
conventional methods give no IgLON-specific signal in non-
neural tissue samples. LSAMP specific signal has not been
detected in the liver and kidney by using northern blot (Pimenta
and Levitt, 2004) or western blot (Innos et al., 2011), although
strong LSAMP specific signals were present for brain samples in
the same immuno/ hybridization membrane. Likewise, NEGR1
specific signal was detectable only in the brain, but not in any
of the non-neural tissues (lung, liver, kidney, testis, muscle)
that were run on the same immunoblot (Funatsu et al., 1999).
By using quantitative polymerase chain reaction (qPCR) that is
widely acknowledged as the most sensitive method to quantify
small amounts of nucleic acids (Svec et al., 2015), we detected
the expression of both Lsamp 1a and 1b transcripts in the
liver and kidney in the current study and Negr1 transcript was
detectable in all non-neural tissues that were tested. With a few
exceptions, the IgLON transcripts could be detected in all tissues
outside CNS that we studied: in the skeletal muscles, heart, lung,
liver, small intestine, adrenal glands, kidney, male ureter, ductus
deferens, testis, ovary, and uterus (Table 1).We have used relative
quantification for the analysis of IgLON expression in both
neural and non-neural tissues, aiming to evaluate the relative
difference in expression levels in the brain and other organs.
The expression difference between brain and other organs was
highly different across IgLON genes ranging from 4.5-fold
(Iglon5 transcript) to nearly 100-fold (Opcml 1b transcript). This
differences explain why IgLON proteins/transcripts often remain
undetectable in non-neural tissues where the copy number of
IgLON transcripts is low and not detectable by expression
techniques with modest sensitivity, such as western blot and
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northern blot. Iglon5 seems to be different in its relatively
homogenous body-wide expressional distribution and is not
characterized by obvious expressional dominance in the central
nervous system which is a definite characteristic of other IgLON
family members.
Outside CNS, the highest expression level was observed
for Lsamp 1b transcript in the heart, which is in line
with considerable evidence suggesting that IgLONs, specifically
Lsamp and Ntm, may have additional functions in the human
cardiovascular system (Wang et al., 2008; Luukkonen et al.,
2012; Cao et al., 2015; Dungan et al., 2016). However, data from
knockout mouse models has demonstrated that deletion of either
Lsamp, Ntm, or Opcml individually, or Opcml and Ntm together
as a double heterozygote, does not result in apparent cardiac
phenotype (Innos et al., 2011; Ye et al., 2014).
The accumulating data indicating that IgLON neural adhesion
molecules can function as tumor-suppressor genes in a number
of organs also outside CNS (Sellar et al., 2003; Cui et al.,
2008; Kim et al., 2014; Coccaro et al., 2015) has been rather
unexpected as the expression-distribution has been suggested to
be limited to CNS. Mutations or epigenetic alterations in the
IgLON genes have been linked with different tumor types in the
CNS (Reed et al., 2007; Minhas et al., 2013) but also in many
other tissue types including osteosarcomas in the bone tissue
(Barøy et al., 2014) and malignant processes involving blood
cells, such as acute lymphoblastic leukemia (Kang et al., 2012)
and acute myeloid leukemia (Coccaro et al., 2015). Majority of
IgLON-related tumors in non-neural tissues involve urogenital
system and reproductive system. Evidence links OPCML gene
with epithelial ovarian cancer (Sellar et al., 2003; Ntougkos
et al., 2005). Mutations in the NEGR1 gene have been related
to Wilms tumor, which leads to malignant process in the kidney
(Karlsson et al., 2011), additionally LSAMP promoter has been
inactivated by methylation in a considerable amount of clear
cell renal carcinomas. One or multiple members of the IgLON
family have also been altered in bladder cancer (Pascal et al.,
2009), prostate cancer (Huang et al., 2013), uterine leiomyomata
(Crabtree et al., 2009), and in the testicular cancer (Cheung
et al., 2010). Here, we confirmed widespread expression of
IgLON transcripts in the urogenital and reproductive system.
Additionally, our data suggests IgLON adhesion molecules to
mediate intercellular interactions also in non-neural tissues
which is likely the mechanism for the tumor formation and
invasion (Shimizu et al., 2016) often reported in case of disruptive
mutations in IgLON genes.
Expression of IgLON Transcripts in the
Brain
Twin promoters 1a and 1b of Opcml, Ntm, and Lsamp
(Figures 3A–F) reveal remarkable variety in the activity levels
in different brain areas as we have previously demonstrated for
Lsamp gene (Philips et al., 2015). Certain expression patterns
can be detected between promoters: whereas 1b promoters are
highly expressed in the cerebellum, 1a promoters, on the contrast,
have stronger expression in the frontal cortex and in certain basal
forebrain structures, such as dorsal striatum and hippocampus.
The general expression patterns of Lsamp transcripts is in line
with our previous studies (Heinla et al., 2015; Philips et al., 2015).
As a novel finding, Lsamp 1a promoter has strong activity in the
eye. The expressional activity of Ntm 1a and 1b promoters is
remarkably different as well. 1a promoter activity is the highest
in the frontal cortex and thalamus (Figure 3C), whereas 1b is
the most active in the cerebellum (Figure 3D). In the light of
these results, it appears that the high levels of Ntm, previously
detected in the thalamus, basal ganglia, and dorsal striatum
(Struyk et al., 1995), is triggered byNtm 1a promoter, whereas the
high expression of Ntm in the cerebellum, detected in the same
study, is initiated from Ntm 1b promoter. Lower levels of Ntm
in the brain stem nuclei and spinal cord (Struyk et al., 1995; Gil
et al., 2002) represent Ntm 1a activity. Ntm 1a promoter activity
was minimal in the brainstem in the current study.
Likewise, the expression activity of Opcml 1a and 1b
promoters varies highly. Considering our current results, it
appears that the high levels of Opcml, previously detected
in the hippocampus of adult rat (Hachisuka et al., 2000),
is triggered by Opcml 1a promoter. The highest expression
of Opcml 1a was detected in the frontal cortex (Figure 3E),
whereas the highest expression of Opcml 1b was measured in
the cerebellum (Figure 3F) where 1a promoter has no detectable
activity. However, both promoters in Opcml are highly active
in the olfactory bulb. The expression of Opcml has been
well characterized in the primary visual cortex of the cat (Li
et al., 2006). The expression activity in the occipital lobe was
mild and nearly equal for both 1a and 1b promoters in our
current study. The high expression activity of Negr1 in the
frontotemporal cortex has been described previously by using
in situ hybridization (Brauer et al., 2000) and highest levels of
Negr1 in the frontal and temporal cortex were also detected
in the current study. Here, we demonstrate for the first time
the expression profile of Iglon5 transcript. The levels of Iglon5
transcript were the highest in the thalamus and brainstem
(namely pons and medulla); the expression activity was also
relatively high in non-neural organs and tissue types, being
roughly only 4.5-fold lower than the average Iglon5 expression
in brain areas.
Intra-Family Interactions of IgLON Family
Several cell culture experiments suggest LSAMP and other
IgLON proteins to have vital functions in the development
of neural circuits, as LSAMP has been shown to regulate
the formation of septohippocampal (Keller et al., 1989),
intrahippocampal (Pimenta et al., 1995), and thalamic (Mann
et al., 1998) connections. Likewise, NTM has been shown to
participate in the axon fasciculation of cerebellar systems, in
the formation of excitatory synapses (Chen et al., 2001) and
neurite outgrowth (Gil et al., 1998). Despite a seemingly essential
function in brain development, no major changes have been
reported in the gross anatomy in the brains of mice deficient for
either Lsamp (Philips et al., 2015) or Negr1 (Lee et al., 2012).
Considering the high levels of intra-family homology shared
by IgLON adhesion molecules and functional compensation
observed between intra-family genes of other cell adhesion
molecules (Giagtzoglou et al., 2009; Bedner et al., 2012) led us
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to investigate the potential compensatory effects in the level of
IgLON transcripts/proteins in the absence of one or two family
members.
Surprisingly, in the current study we found no increase of
the transcripts of other IgLON family genes in the frontal cortex
of mice lacking Ntm, Lsamp, or both the genes (Figure 4). On
the contrary, we demonstrated significantly reduced expression
of Ntm 1a mRNA and NEGR1 protein in Lsamp-deficient mice.
Negr1 transcript was significantly reduced in the frontal cortex
of Lsamp-deficient mice compared with the frontal cortex of
mice lacking Ntm. The double-mutant mice itself revealed no
significant changes compared to wild-type mice. Moreover, we
found the intra-family expressions of IgLON transcripts across
individuals to be highly correlated (Supplementary Tables S18,
S19). Strict maintenance of definite expression pattern of IgLONs
in different brain areas or cell types can be necessary for
normal function of neural circuits; loss of binding partner may
lead to down-regulation of other family member to inhibit
unbalanced dimer formation. Our current results suggest that
IgLON adhesion molecules perform specific functions and lack
of one family member is not compensated by the quantitative
increase of the others. Rather, the family seems to function
collectively in a balanced manner as suggested by previous
studies demonstrating highly specific complexes and interactions
between IgLON family members (Mann et al., 1998; Gil et al.,
2002; Reed et al., 2004).
The reduced expression of other IgLON transcripts in
Lsamp-deficient brain seems to be specific to certain brain
areas or cell types: in our study the changes were detectable
in the frontal cortex but not in the hippocampal area. In
the hippocampus, the only significant effects were changes in
the level of Iglon5 expression in Lsamp-deficient hippocampi
compared with hippocampi of wild type mice and mice lacking
bothNtm and Lsamp. The result has no clear explanation as there
is no data about the interactions of Iglon5 with other IgLON
family members. However, our results suggest that the intra-
family interactions including potential compensatory effects can
be tissue specific.
As previously published data links IgLON family members
with synaptic plasticity (Hashimoto et al., 2009; Qiu et al., 2010;
Heinla et al., 2015), we used our mutant mouse models also to
explore the intra-family interactions acting on the expression
levels of well-described marker of synaptogenesis, Synaptophysin
(Syp). We detected significant upregulation of Syp mRNA in the
hippocampi of mice lacking Ntm, but not in mice lacking Lsamp
(Figure 6). The results suggest that Ntm could have an inhibitory
impact on the reconstructive activity in the hippocampal
synapses. Moreover, as Syp is not significantly increased in
the hippocampi of mice lacking both Ntm and Lsamp, we can
hypothesize that LSAMP is the real enhancer for processes that
are correlated with Syp activity in the hippocampus. Indeed,
overexpression of LSAMP in hippocampal cell culture has
been shown to have a stimulating effect on synapse formation
(Hashimoto et al., 2009). Additionally, overexpression of NTM
in the same experiment had no effect on the synapse marker,
supporting the notion of NTM as an inhibiting/neutral factor
for synaptogenesis. Hashimoto et al. (2009) also overexpressed
both NTM and LSAMP, which resulted in a decrease of synapses.
Our data combined with previously published results suggest
that NTM and LSAMP are involved in synaptogenesis, having
antagonistic functions which could be characteristic for the whole
IgLON family.
In conclusion, we show that important regulatory
mechanisms of IgLON genes derive from their genomic
organization. Remarkable variety in the activity levels of 1a
and 1b promoters both in the brain and a wide spectrum of
tissues outside the central nervous system, suggests a complex
regulation of IgLONs by alternative signal peptides driven
by 1a and 1b promoters. As the lack of one or two family
members is not compensated by a systematic quantitative
increase of the other members, IgLON proteins seem to have
limited redundancy despite highly homologous sequence in
both DNA and amino acid level. The antagonistic impact
of individual IgLONs in functional systems is supported
here by differential Syp expression in deletional mutants
of IgLON members. Altogether our results emphasize
the importance of studying IgLON family members as a
complex functional system when interpreting their biological
role.
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